Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue

British Journal of Haematology

Volumn 137, Issue 5, 2007, Pages 436-442

  Nolan, L ^a   Lorigan, P ^b,c   Chilton, S ^a   Newman, J ^a   Else, R ^b   Smith, P ^d   Linch, D ^d   Sweetenham, J W ^e   Johnson, P W ^a,f  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e LERNER RESEARCH INSTITUTE   (United States)

^f SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

CD34; Growth factors; High dose therapy; Lymphoma; Stem cell transplantation

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; CARMUSTINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG USE; FEMALE; FOLLICULAR LYMPHOMA; HEMATOPOIESIS; HODGKIN DISEASE; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTICENTER STUDY; MYELOABLATIVE CONDITIONING; NEUTROPHIL; NEUTROPHIL COUNT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SINGLE BLIND PROCEDURE; STANDARD; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELL COUNT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; NEUTROPHILS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 34247892147     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06587.x     Document Type: Article

References (25)

1. Bence-Bruckler, I., Bredeson, C., Atkins, H., McDiarmid, S., Hamelin, L., Hopkins, H., Perry, G., Genest, P. Huebsch, L. (1998) A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplantation, 22, 965 969.
2. Bolwell, B., Goormastic, M., Dannley, R., Andresen, S., Overmoyer, B., Mendez, Z., Kalaycioglu, M., DeMars, D., Wise, K. Pohlman, B. (1997) G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day. Bone Marrow Transplantation, 19, 215 219.
3. Bolwell, B.J., Pohlman, B., Andresen, S., Kalaycio, M., Goormastic, M., Wise, K., Wakeling, A., Dannley, R. Overmoyer, B. (1998) Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplantation, 21, 369 373.
4. Brugger, W., Birken, R., Bertz, H., Hecht, T., Pressler, K., Frisch, J., Schulz, G., Mertelsmann, R. Kanz, L. (1993) Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. British Journal of Haematology, 84, 402 407.
5. Colby, C., McAfee, S.L., Finkelstein, D.M. Spitzer, T.R. (1998) Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation, 21, 1005 1010.
6. Dekker, A., Bulley, S., Beyene, J., Dupuis, L.L., Doyle, J.J. Sung, L. (2006) Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. Journal of Clinical Oncology, 24, 5207 5215.
7. Gianni, A.M. (1994) Where do we stand with respect to the use of peripheral blood progenitor cells? Annals of Oncology, 5, 781 784.
8. Hartmann, O., Le Corroller, A.G., Blaise, D., Michon, J., Philip, I., Norol, F., Janvier, M., Pico, J.L., Baranzelli, M.C., Rubie, H., Coze, C., Pinna, A., Meresse, V. Benhamou, E. (1997) Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Annals of Internal Medicine, 126, 600 607.
9. Johnson, P., George, S., Agrawal, S., Bennett-Lloyd, B. (2003) Improving outcomes in haematological cancers. In : The Evidence, pp. 205 206. NICE, York.
10. Kawano, Y., Takaue, Y., Mimaya, J., Horikoshi, Y., Watanabe, T., Abe, T., Shimizu, Y., Matsushita, T., Kikuta, A., Watanabe, A., Iwai, A., Ito, E., Endo, M., Kodani, N., Ohta, S., Gushi, K., Azuma, H., Etoh, T., Okamoto, Y., Amano, K., Hattori, H., Eguchi, H. Kuroda, Y. (1998) Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. The Japanese Cooperative Study Group of PBSCT. Blood, 92, 4040 4046.
11. Klumpp, T.R., Mangan, K.F., Goldberg, S.L., Pearlman, E.S. Macdonald, J.S. (1995) Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. Journal of Clinical Oncology, 13, 1323 1327.
12. Linch, D.C., Milligan, D.W., Winfield, D.A., Kelsey, S.M., Johnson, S.A., Littlewood, T.J., Smith, G.M., Hutchinson, R.M., Goldstone, A.H., Fielding, A.K. Vaughan Hudson, G. (1997) G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. British Journal of Haematology, 99, 933 938.
13. McQuaker, I.G., Hunter, A.E., Pacey, S., Haynes, A.P., Iqbal, A. Russell, N.H. (1997) Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. Journal of Clinical Oncology, 15, 451 457.
14. Pagliuca, A., Carrington, P.A., Pettengell, R., Tule, S. Keidan, J. (2003) Guidelines on the use of colony-stimulating factors in haematological malignancies. British Journal of Haematology, 123, 22 33.
15. Schmitz, N., Linch, D.C., Dreger, P., Goldstone, A.H., Boogaerts, M.A., Ferrant, A., Demuynck, H.M., Link, H., Zander, A. Barge, A. (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet, 347, 353 357.
16. Schmitz, N., Ljungman, P., Cordonnier, C., Kempf, C., Linkesch, W., Alegre, A., Solano, C., Simonsson, B., Sonnen, R., Diehl, V., Fischer, T., Caballero, D., Littlewood, T., Noppeney, R., Schafhausen, P., Jost, L., Delabarre, F. Marcus, R. (2004) Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplantation, 34, 955 962.
17. Shimazaki, C., Oku, N., Uchiyama, H., Yamagata, N., Tatsumi, T., Hirata, T., Ashihara, E., Okawa, K., Goto, H., Inaba, T., et al 1994) Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplantation, 13, 271 275.
18. Shpall, E.J., Jones, R.B., Bearman, S.I., Franklin, W.A., Archer, P.G., Curiel, T., Bitter, M., Claman, H.N., Stemmer, S.M., Purdy, M., Myers, S.E., Hami, L., Taffs, S., Heimfeld, S., Hallogan, J. Berenson, R.J 1994) Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. Journal of Clinical Oncology, 12, 28 36.
19. Smith, T.J., Hillner, B.E., Schmitz, N., Linch, D.C., Dreger, P., Goldstone, A.H., Boogaerts, M.A., Ferrant, A., Link, H., Zander, A., Yanovich, S., Kitchin, R. Erder, M.H. (1997) Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. Journal of Clinical Oncology, 15, 5 10.
20. Smith, T.J., Khatcheressian, J., Lyman, G.H., Ozer, H., Armitage, J.O., Balducci, L., Bennett, C.L., Cantor, S.B., Crawford, J., Cross, S.J., Demetri, G., Desch, C.E., Pizzo, P.A., Schiffer, C.A., Schwartzberg, L., Somerfield, M.R., Somlo, G., Wade, J.C., Wade, J.L., Winn, R.J., Wozniak, A.J. Wolff, A.C. (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology, 24, 3187 3205.
21. Spitzer, G., Adkins, D.R., Spencer, V., Dunphy, F.R., Petruska, P.J., Velasquez, W.S., Bowers, C.E., Kronmueller, N., Niemeyer, R. McIntyre, W. (1994) Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. Journal of Clinical Oncology, 12, 661 670.
22. Stahel, R.A., Jost, L.M., Honegger, H., Betts, E., Goebel, M.E. Nagler, A. (1997) Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. Journal of Clinical Oncology, 15, 1730 1735.
23. Suh, C., Kim, H.J., Kim, S.H., Kim, S., Lee, S.J., Lee, Y.S., Kim, E.K., Kim, S.B., Lee, J.S., Kim, M.W., Kim, K. Yoon, S.S. (2004) Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses. Transfusion, 44, 533 538.
24. To, L.B., Roberts, M.M., Haylock, D.N., Dyson, P.G., Branford, A.L., Thorp, D., Ho, J.Q., Dart, G.W., Horvath, N., Davy, M.L., et al 1992) Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplantation, 9, 277 284.
25. Valteau-Couanet, D., Faucher, C., Auperin, A., Michon, J., Milpied, N., Boiron, J.M., Bourhis, J.H., Gisselbrecht, C., Vernant, J.P., Pinna, A., Bendahmane, B., Delabarre, F. Benhamou, E. (2005) Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplantation, 36, 547 552.